PLCB2 Antibody

What is PLCB2 and why is it important to study?

PLCB2 (phospholipase C beta 2) is a 134 kDa protein that hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which are critical second messengers in cell signaling pathways. PLCB2 is particularly important because:

• It acts as a critical regulator of platelet responses upon activation

• It plays significant roles in various tumor types, including renal cell carcinoma and melanoma

• It functions as a negative regulator of virus-induced inflammatory responses

• It influences cell viability and apoptosis in cancer cells

The diverse functions of PLCB2 make it an important target for research in hematology, oncology, and immunology.

How should I select the appropriate PLCB2 antibody for my experiments?

When selecting a PLCB2 antibody for research, consider the following methodological approach:

• Determine your experimental application: Different antibodies perform optimally in specific applications (WB, IHC, IF/ICC, ELISA). For example, search result shows that Proteintech's Rabbit Polyclonal PLCB2 antibody has been validated for multiple applications including WB, IHC, and IF/ICC.

• Consider species reactivity: Verify that the antibody reacts with your species of interest. Many PLCB2 antibodies are reactive to human, mouse, and rat samples .

• Check validation data: Look for antibodies with comprehensive validation in your application of interest. For example, search result discusses the importance of selecting high-performing antibodies that have been properly validated.

• Review published literature: Check for antibodies that have been successfully used in publications with experimental conditions similar to yours.

• Verify specificity: Use antibodies tested in knockout systems where possible, as this provides definitive evidence of specificity. As noted in search result , "Quantification of immunofluorescence intensity in hundreds of WT and KO cells was performed for each antibody tested."

What are the optimal dilutions for using PLCB2 antibodies in different applications?

Based on validated protocols for PLCB2 antibodies, the following dilution ranges are recommended for different applications:

Note that these ranges serve as starting points, and optimization for your specific experimental conditions is essential. As stated in search result : "It is recommended that this reagent should be titrated in each testing system to obtain optimal results."

How do I optimize a Western blot protocol for detecting PLCB2?

To optimize a Western blot protocol for PLCB2 detection:

• Sample preparation:

  • Use appropriate lysis buffers that preserve phospholipase activity

  • Include phosphatase inhibitors if studying phosphorylation status

• Gel selection:

  • Use 8-10% SDS-PAGE gels to properly resolve the 134 kDa PLCB2 protein

• Transfer conditions:

  • Optimize transfer time for large proteins (typically longer transfers at lower voltage)

  • Consider using PVDF membranes for better protein retention

• Antibody conditions:

  • Start with the manufacturer's recommended dilution (typically 1:500-1:1000)

  • Test different blocking agents (BSA vs. milk) as they may affect antibody performance

  • Optimize incubation times and temperatures

• Controls:

  • Include positive controls such as THP-1 or HL-60 cell lysates, which are known to express PLCB2

  • Consider using recombinant PLCB2 as a standard

  • If available, include samples with PLCB2 knockdown as negative controls

In search result , researchers successfully detected PLCB2 in platelet samples and correlated levels with NF-κB p65 expression, demonstrating that appropriate optimization enables quantitative analysis.

How can I effectively use PLCB2 antibodies for immunofluorescence studies?

For optimal immunofluorescence detection of PLCB2:

• Sample preparation:

  • Fix cells with 4% paraformaldehyde to preserve protein structure

  • Evaluate permeabilization methods (0.1-0.5% Triton X-100 vs. methanol) for optimal antibody access

• Antibody selection and dilution:

  • Choose antibodies specifically validated for IF/ICC applications

  • Start with recommended dilutions (1:50-1:500) and optimize

  • Consider using THP-1 cells as positive controls

• Controls and validation:

  • Include secondary antibody-only controls to assess background

  • If possible, use PLCB2 knockdown or knockout cells as negative controls

  • As described in search result , "Cells were imaged in the same field of view to reduce staining, imaging and image analysis bias...Quantification of immunofluorescence intensity in hundreds of WT and KO cells was performed for each antibody tested."

• Imaging parameters:

  • Standardize exposure settings between samples

  • Consider counterstaining for subcellular markers to determine localization

  • Use Z-stack imaging if evaluating 3D distribution

• Quantification:

  • Establish clear criteria for quantitative analysis

  • Analyze multiple fields and cells for statistical significance

What considerations are important when using PLCB2 antibodies for studying tumor samples?

When investigating PLCB2 in tumor samples, consider these methodological approaches:

• Sample selection and preparation:

  • Include matched normal and tumor tissues from the same patient when possible

  • Consider tissue microarrays for high-throughput analysis

  • Optimize fixation protocols to preserve antigenicity

• Antibody validation:

  • Verify antibody specificity in relevant cell lines first

  • For example, in search result , researchers validated PLCB2 expression in RCC cell lines (ACHN, 786-O) compared to normal renal epithelial cells before examining clinical samples

• Expression analysis:

  • Use multiple methodologies (IHC, WB, qRT-PCR) for confirmation

  • As shown in search result : "We conducted qRT-PCR and Western blot analyses, which showed significantly higher levels of PLCB2 in RCC cell lines (ACHN, 786-O) compared to normal renal epithelial cells"

• Functional correlation:

  • Correlate PLCB2 expression with clinical parameters and outcomes

  • In RCC, high PLCB2 expression was associated with poor prognosis: "survival data from the TCGA database revealed that high PLCB2 expression is significantly associated with poor prognosis"

• Mechanistic studies:

  • Use knockdown/overexpression approaches to investigate functional significance

  • In melanoma studies, "PLCB2-siRNAs significantly suppressed cell viability and promoted cell apoptosis by activating the Ras/Raf/MAPK pathway"

How do I interpret contradictory results between Western blot and immunofluorescence when detecting PLCB2?

When facing discrepancies between Western blot and immunofluorescence results for PLCB2:

• Consider epitope accessibility:

  • Different fixation and sample preparation methods can affect epitope exposure

  • Native protein conformation in IF vs. denatured state in WB may impact antibody recognition

  • Try different antibodies targeting distinct epitopes of PLCB2

• Evaluate protein modifications:

  • Post-translational modifications may affect antibody binding

  • Phosphorylation status of PLCB2 might differ between sample preparations

• Assess subcellular localization:

  • PLCB2 localization can change under different cellular conditions

  • Whole-cell lysates in WB may detect total protein, while IF reveals specific localization patterns

• Review antibody validation data:

  • Some antibodies perform better in specific applications

  • As noted in search result , comprehensive screening of multiple antibodies revealed that some perform well in certain applications but not in others

• Consider technical factors:

  • Optimize both protocols independently

  • Evaluate blocking agents, as some can cause non-specific binding

  • Check for protocol-specific artifacts

• Experimental controls:

  • Include positive and negative controls in both techniques

  • Consider using PLCB2 knockdown or overexpression systems as definitive controls

What are common pitfalls when quantifying PLCB2 expression levels in experimental samples?

When quantifying PLCB2 expression, researchers should be aware of these potential issues:

• Reference gene/protein selection:

  • Choose appropriate housekeeping genes/proteins for normalization

  • In search result , researchers normalized PLCB2 against actin when quantifying protein levels in platelets

  • Verify that the reference gene is stable across your experimental conditions

• Antibody specificity issues:

  • Non-specific bands in Western blots may complicate quantification

  • Verify the molecular weight of detected bands (PLCB2 should be ~134 kDa)

• Dynamic range limitations:

  • Ensure signal is within the linear range of detection

  • Avoid overexposed Western blots or saturated immunofluorescence images

• Sample variability:

  • Account for cell-to-cell variability in expression levels

  • In search result , researchers analyzed PLCB2 in platelets from 17 healthy subjects and found correlation with NF-κB p65 levels (r=0.76, p=0.0005)

• Technical replication:

  • Include sufficient technical and biological replicates

  • Report statistical methods used for quantification

• Consideration of isoforms or modifications:

  • Be aware that different PLCB2 isoforms or post-translational modifications might affect quantification

  • Use appropriate controls to account for these variables

How can PLCB2 antibodies be used to investigate signaling pathways in cancer progression?

PLCB2 antibodies can be valuable tools for investigating signaling pathways in cancer through these methodological approaches:

• Co-immunoprecipitation (Co-IP) studies:

  • Use PLCB2 antibodies to pull down protein complexes

  • Identify interacting partners through mass spectrometry or Western blotting

  • This approach can reveal novel signaling connections

• Phosphorylation state analysis:

  • Use phospho-specific antibodies in conjunction with total PLCB2 antibodies

  • Monitor activation states in response to stimuli or drug treatments

• Pathway interaction studies:

  • As demonstrated in search result , PLCB2 was found to interact with the PI3K/AKT pathway in renal cell carcinoma: "Our study identifies PLCB2 as a significant regulator of EMT in RCC through its activation of the PI3K/AKT pathway"

  • In melanoma, PLCB2 was connected to the Ras/Raf/MAPK pathway

• In vivo imaging:

  • Use fluorescently labeled antibodies for intravital microscopy

  • Track PLCB2-expressing cells in tumor microenvironments

• Functional genomics integration:

  • Combine antibody-based detection with CRISPR screens or RNAi studies

  • As shown in search result , researchers used siRNA to reduce PLCB2 expression and observed effects on cell proliferation, colony formation, and migration

• Therapeutic target validation:

  • Use antibodies to verify target engagement in drug development

  • Search result suggests PLCB2 as a potential therapeutic target: "Our study highlights PLCB2 as a potential alternative target and provides a foundation for developing PLCB2-specific inhibitors"

How can I design experiments to study the relationship between PLCB2 and inflammatory responses?

To investigate PLCB2's role in inflammatory responses, consider this experimental design approach:

• Expression analysis in inflammatory conditions:

  • Compare PLCB2 expression in resting vs. activated immune cells

  • Monitor temporal changes during inflammatory responses

• Genetic manipulation models:

  • Use PLCB2 knockout models to study inflammatory phenotypes

  • In search result , researchers used Plcb2-/- mice to demonstrate that "PLCβ2 negatively regulates virus-induced pro-inflammatory responses"

  • The study found that "Skeletal muscle tissue from Plcb2−/− mice had significantly higher mRNA levels of Tnf, Il6, and Il12 compared with wild-type mice"

• Mechanistic studies:

  • Investigate how PLCB2 regulates inflammatory pathways

  • Search result revealed that "PLCβ2 down-regulates virus-induced activation of TAK1, as well as the subsequent production of proinflammatory cytokines through the degradation of PIP2"

• Structure-function analysis:

  • Use mutant forms of PLCB2 to identify domains important for inflammatory regulation

  • As noted in search result , "Expression of wild-type PLCβ2 inhibited TAK1-induced activation of NF-κB and AP-1 reporter gene, but the phospholipase-inactive mutant did not"

• Therapeutic implications:

  • Test whether PLC activators could modulate inflammatory responses

  • Search result suggests that "treatment with a PLC activator could serve as a new therapeutic strategy for viral infections"

What experimental approaches can reveal the role of PLCB2 in cell survival and apoptosis?

To investigate PLCB2's role in cell survival and apoptosis, implement these methodological approaches:

• Expression modulation:

  • Use siRNA knockdown and overexpression of PLCB2

  • In search result , researchers demonstrated: "A significant decrease in the cell viability was noted in the A375 cells treated with the PLCB2-siRNAs (siPLCB2) when compared to the controls at 24, 48 and 72 h after transfection (100, 79.3 and 58.2%, respectively)"

  • Conversely, "cell viability in the A375 cells treated with the PLCB2 plasmid (PLCB2) was significantly increased (100, 178.5 and 207.4%, respectively)"

• Apoptosis assays:

  • Use flow cytometry with Annexin V/PI staining to quantify apoptotic cells

  • In melanoma cells, "Flow cytometric analysis indicated that siPLCB2 significantly enhanced the apoptotic rate of the A375 cells"

• Molecular pathway analysis:

  • Monitor key apoptosis regulators through Western blotting

  • "p53, cleaved caspase-3 and Bax mRNA and protein expression levels were significantly increased in the siPLCB2 group, compared to the Ctrl and Ctrl_NC groups"

  • "Bcl-2 protein expression level was significantly upregulated in the PLCB2 group compared with the Ctrl and Ctrl_NC groups"

• Colony formation assays:

  • Assess long-term survival and proliferative capacity

  • "The results showed that low expression of PLCB2 significantly suppressed cell growth and that high expression of PLCB2 significantly promoted cell growth"

• In vivo xenograft models:

  • Evaluate the effect of PLCB2 modulation on tumor growth in animal models

  • Consider combining with apoptosis-inducing treatments to assess sensitization

How does PLCB2 expression correlate with clinical outcomes in different cancer types?

Research has revealed significant correlations between PLCB2 expression and clinical outcomes in multiple cancer types:

• Renal Cell Carcinoma (RCC):

  • "Survival data from the TCGA database revealed that high PLCB2 expression is significantly associated with poor prognosis"

  • PLCB2 promotes tumor progression by enhancing cell proliferation and migration in RCC cell lines

• Melanoma:

  • PLCB2 enhances melanoma cell viability and reduces apoptosis

  • Knockdown of PLCB2 in melanoma cells increases expression of pro-apoptotic factors including p53, cleaved caspase-3, and Bax

• Mechanistic insights:

  • In RCC, PLCB2 appears to activate the PI3K/AKT pathway, promoting EMT (epithelial-mesenchymal transition)

  • In melanoma, PLCB2 interacts with the Ras/Raf/MAPK pathway

• Therapeutic implications:

  • "Our study highlights PLCB2 as a potential alternative target and provides a foundation for developing PLCB2-specific inhibitors"

  • "Current evidence indicates that small-molecule inhibitors represent a viable approach, with high-throughput screening and molecular optimization offering the potential to develop drugs that are both highly selective and exhibit minimal side effects"

• Research considerations:

  • Combined targeting approaches may be beneficial: "Based on our study of PLCB2, combination therapies targeting PLCB2 alongside related molecules, such as PI3K/AKT, may further enhance therapeutic efficacy"

What is the molecular mechanism by which PLCB2 regulates transcriptional activation in immune responses?

Recent research has elucidated several molecular mechanisms through which PLCB2 regulates transcriptional activation in immune responses:

• Regulation of NF-κB signaling:

  • PLCB2 expression is regulated by NF-κB via a consensus site in the PLCB2 promoter region

  • "Our studies provide the first evidence that NF-kB regulates PLC-β2 expression"

  • There exists a regulatory feedback loop, as "NF-κB regulates MK/platelet PLC-β2 expression"

• Modulation of TAK1 activation:

  • PLCβ2 negatively regulates virus-induced activation of TAK1

  • "PLCβ2 down-regulates virus-induced activation of TAK1, as well as the subsequent production of proinflammatory cytokines through the degradation of PIP2"

• Phospholipase activity requirement:

  • The catalytic activity of PLCB2 is essential for its regulatory function

  • "Expression of wild-type PLCβ2 inhibited TAK1-induced activation of NF-κB and AP-1 reporter gene, but the phospholipase-inactive mutant did not"

  • Studies with phospholipase-inactive mutants (H327A and H374A) demonstrated that "mutation of phospholipase-active site abolished PLCβ2's inhibition on TAB1 and TAK1 interaction and TAK1 phosphorylation"

• Impact on cytokine production:

  • PLCB2 deficiency leads to increased proinflammatory cytokine production

  • "Skeletal muscle tissue from Plcb2−/− mice had significantly higher mRNA levels of Tnf, Il6, and Il12 compared with wild-type mice"

• Therapeutic potential:

  • "Our findings indicate that PLCβ2 is a negative regulator of the virus-induced inflammatory response and treatment with a PLC activator could serve as a new therapeutic strategy for viral infections"

This research provides important insights into how PLCB2 functions as a critical regulator of immune responses and highlights its potential as a therapeutic target in inflammatory conditions.

How can I design a PLCB2 knockdown experiment to study its function in primary cells?

When designing PLCB2 knockdown experiments in primary cells, consider these methodological approaches:

• Knockdown strategy selection:

  • For transient knockdown, use siRNA as demonstrated in several studies

  • For stable knockdown, consider lentiviral shRNA delivery

  • For complete knockout, CRISPR-Cas9 systems may be appropriate

• Delivery optimization:

  • Primary cells often have lower transfection efficiency than cell lines

  • Test multiple transfection reagents specifically designed for primary cells

  • Consider electroporation for hard-to-transfect primary cell types

  • Optimize cell density and timing of experiments

• Validation approach:

  • Confirm knockdown efficiency at both mRNA and protein levels

  • As shown in search result : "We used qRT-PCR, immunofluorescence, and Western blot analyses to confirm PLCB2 reduction. All methods showed significant decreases in PLCB2 mRNA and protein levels"

• Functional readouts:

  • Design assays relevant to cell type and PLCB2 function

  • For immune cells, measure cytokine production (TNF, IL-6, IL-12)

  • For cancer cells, assess proliferation, migration, and apoptosis

  • Consider calcium signaling assays, as PLCB2 regulates Ca²⁺ mobilization

• Controls:

  • Include non-targeting siRNA controls

  • Consider rescue experiments with siRNA-resistant PLCB2 constructs

  • Include wild-type versus phospholipase-inactive mutants to distinguish enzymatic from scaffolding functions

How should I approach studying post-translational modifications of PLCB2 using antibody-based methods?

To effectively study post-translational modifications (PTMs) of PLCB2:

• Modification-specific antibody selection:

  • Use antibodies specific to phosphorylated, ubiquitinated, or other modified forms of PLCB2

  • Validate specificity using appropriate positive and negative controls

  • Consider generating custom antibodies if commercial options are unavailable

• Sample preparation optimization:

  • Include phosphatase inhibitors when studying phosphorylation

  • Add proteasome inhibitors when examining ubiquitination

  • Use specialized lysis buffers that preserve the modification of interest

• Enrichment strategies:

  • Perform immunoprecipitation with total PLCB2 antibody followed by Western blotting with modification-specific antibodies

  • Consider using phospho-enrichment techniques for mass spectrometry analysis

• Stimulation conditions:

  • Design experiments with appropriate stimuli known to induce the modification

  • Include time course analyses to capture transient modifications

  • In platelets, PMA treatment can be used to induce megakaryocytic transformation and affect PLCB2 expression

• Functional correlation:

  • Correlate modifications with PLCB2 enzymatic activity

  • Examine how modifications affect protein-protein interactions

  • Study the impact on downstream signaling events

• Site-directed mutagenesis:

  • Generate PLCB2 mutants at potential modification sites

  • Compare wild-type and mutant PLCB2 function in cellular assays

  • Similar to the approach in search result , where researchers studied phospholipase-inactive mutants (H327A and H374A)

By following these methodological approaches, researchers can effectively investigate the complex regulatory mechanisms controlling PLCB2 function through post-translational modifications.